SCHEDULE: MAK Capital Discloses 6.7% Stake in Standard BioTools
Schedule 13G/A (Beneficial Ownership Amendment)
Investment firm MAK Capital and Michael A. Kaufman have reported a 6.7% beneficial ownership stake in Standard BioTools Inc.
Summary
- MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman filed an amendment to their Schedule 13G regarding their holdings in Standard BioTools Inc.
- The reporting persons collectively hold 26,172,626 shares of common stock.
- This position represents 6.7% of the total outstanding shares of Standard BioTools Inc., based on 390,368,119 shares outstanding as of May 4, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing institutional interest in the company.
Positives
- The filing indicates a significant institutional investment position, suggesting confidence in the company's long-term prospects.
Negatives
- None identified in this regulatory disclosure.
Risks
- The reporting persons hold these shares for investment purposes and have certified that they are not currently seeking to change or influence the control of the issuer.
Future Outlook
The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that institutional filings like this are standard in the biotechnology sector, where large investment firms often take significant positions in companies undergoing strategic transitions or growth phases.
Comparison to Industry Standards
- The filing follows standard SEC regulatory requirements for beneficial ownership reporting under Rule 13d-1.
- The 6.7% stake is consistent with typical activist or long-term institutional investment thresholds in mid-cap biotech firms.
Stakeholder Impact
- Shareholders may view the continued presence of a significant institutional investor as a sign of stability.
Next Steps
- The reporting persons will continue to monitor their investment in Standard BioTools Inc.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of event requiring the filing of the statement. |
| 05/04/2026 | Date used for total shares outstanding calculation. |
| 05/06/2026 | Date of the Issuer's Quarterly Report on Form 10-Q. |
| 05/15/2026 | Date of the Schedule 13G/A filing and signature date. |
Keywords
Standard BioTools, MAK Capital, Schedule 13G, Institutional Ownership, LAB, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.